ipamorelin vs ghrp-2 ghrp-6 cortisol prolactin CJC-1295 (Mod GRF 1-29) & & - 9MG ipamorelin vs ghrp-2 ghrp-6 cortisol

Jensterle et al., 2020)

testing is not necessary

Breaks make sense for users experiencing treatment plateau where benefits cease increasing despite continued application suggesting diminishing returns from ongoing use, comfortable with some benefit decline during off periods accepting fluctuation in skin quality, budget-conscious seeking to minimize annual treatment costs through intermittent purchasing, philosophically preferring avoiding indefinite dependency on any skincare product, planning life changes incompatible with consistent application (extended travel, relocation, financial shifts), and wanting to assess whether improvements prove durable or require continuous maintenance before committing to indefinite treatment

Potential Causes of Immune-Related Adverse Events Researchers are still trying to ascertain the underlying cause of irAEs from treatment with checkpoint inhibitors